---
layout: default
title: Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation
---

# Accelerating MHC-II Epitope Discovery via Multi-Scale Prediction in Antigen Presentation

**arXiv**: [2512.14011v1](https://arxiv.org/abs/2512.14011) | [PDF](https://arxiv.org/pdf/2512.14011.pdf)

**ä½œè€…**: Yue Wan, Jiayi Yuan, Zhiwei Feng, Xiaowei Jia

**åˆ†ç±»**: cs.LG, q-bio.QM

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

<<<<<<< HEAD
**æå‡ºå¤šå°ºåº¦é¢„æµ‹æ¡†æ¶ä»¥åŠ é€ŸMHC-IIæŠ—åŸè¡¨ä½å‘ç°ï¼Œè§£å†³å…ç–«æ²»ç–—ä¸­è¡¨ä½é¢„æµ‹çš„æŒ‘æˆ˜**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **ä¸–ç•Œæ¨¡å‹**

**å…³é”®è¯**: `MHC-IIè¡¨ä½é¢„æµ‹` `è®¡ç®—å…ç–«æ²»ç–—` `å¤šå°ºåº¦æœºå™¨å­¦ä¹ ` `æŠ—åŸå‘ˆé€’å»ºæ¨¡` `æ•°æ®é›†æ ‡å‡†åŒ–` `æ¨¡å—åŒ–æ¡†æ¶` `å…ç–«ååº”é¢„æµ‹` `ç”Ÿç‰©ä¿¡æ¯å­¦`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šMHC-IIæŠ—åŸè¡¨ä½é¢„æµ‹é¢ä¸´æ•°æ®é›†å°ã€æ ‡å‡†åŒ–ä¸è¶³ã€ç»“åˆç‰¹å¼‚æ€§å¤æ‚ç­‰æŒ‘æˆ˜ï¼Œé™åˆ¶äº†å…ç–«æ²»ç–—ç ”ç©¶ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæ„å»ºæ ‡å‡†åŒ–æ•°æ®é›†ï¼Œå®šä¹‰å¤šå°ºåº¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé‡‡ç”¨æ¨¡å—åŒ–æ¡†æ¶è¿›è¡Œæ¨¡å‹è¯„ä¼°ä¸è®¾è®¡åˆ†æã€‚
3. å®éªŒæˆ–æ•ˆæœï¼šé€šè¿‡å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶åŸºå‡†æµ‹è¯•ç°æœ‰æ¨¡å‹ï¼Œæä¾›å…¨é¢åˆ†æï¼Œä¸ºæœªæ¥ç ”ç©¶å¥ å®šåŸºç¡€ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç”±ä¸»è¦ç»„ç»‡ç›¸å®¹æ€§å¤åˆä½“IIï¼ˆMHC-IIï¼‰è›‹ç™½å‘ˆé€’çš„æŠ—åŸè¡¨ä½åœ¨å…ç–«æ²»ç–—ä¸­èµ·ç€è‡³å…³é‡è¦çš„ä½œç”¨ã€‚ç„¶è€Œï¼Œä¸è®¡ç®—å…ç–«æ²»ç–—ä¸­æ›´å¹¿æ³›ç ”ç©¶çš„MHC-Iç›¸æ¯”ï¼ŒMHC-IIæŠ—åŸè¡¨ä½çš„ç ”ç©¶ç”±äºå…¶å¤æ‚çš„ç»“åˆç‰¹å¼‚æ€§å’Œæ¨¡ç³Šçš„åŸºåºæ¨¡å¼è€Œé¢ä¸´æ›´å¤šæŒ‘æˆ˜ã€‚å› æ­¤ï¼Œç°æœ‰çš„MHC-IIç›¸äº’ä½œç”¨æ•°æ®é›†æ¯”MHC-Içš„æ•°æ®é›†æ›´å°ä¸”æ ‡å‡†åŒ–ç¨‹åº¦æ›´ä½ã€‚ä¸ºåº”å¯¹è¿™äº›æŒ‘æˆ˜ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ä¸ªä»å…ç–«è¡¨ä½æ•°æ®åº“ï¼ˆIEDBï¼‰å’Œå…¶ä»–å…¬å…±æ¥æºç²¾å¿ƒæ•´ç†çš„æ•°æ®é›†ã€‚å®ƒä¸ä»…æ‰©å±•å’Œæ ‡å‡†åŒ–äº†ç°æœ‰çš„è‚½-MHC-IIæ•°æ®é›†ï¼Œè¿˜å¼•å…¥äº†ä¸€ä¸ªå…·æœ‰æ›´ä¸°å¯Œç”Ÿç‰©å­¦èƒŒæ™¯çš„æ–°å‹æŠ—åŸ-MHC-IIæ•°æ®é›†ã€‚åˆ©ç”¨è¯¥æ•°æ®é›†ï¼Œæˆ‘ä»¬åˆ¶å®šäº†è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŸå‘ˆé€’ä¸‰ä¸ªä¸»è¦çš„æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé€æ­¥æ•æ‰MHC-IIæŠ—åŸå‘ˆé€’é€”å¾„ä¸­æ›´å¹¿æ³›çš„ç”Ÿç‰©è¿‡ç¨‹ã€‚æˆ‘ä»¬è¿›ä¸€æ­¥é‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶å¯¹ç°æœ‰æ¨¡å‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå¹¶é€šè¿‡æ¨¡å—åŒ–æ¡†æ¶å¯¹è¯¥é—®é¢˜çš„å„ç§å»ºæ¨¡è®¾è®¡è¿›è¡Œå…¨é¢åˆ†æã€‚æ€»ä½“è€Œè¨€ï¼Œè¿™é¡¹å·¥ä½œä¸ºæ¨è¿›è®¡ç®—å…ç–«æ²»ç–—æä¾›äº†å®è´µèµ„æºï¼Œä¸ºæœªæ¥æœºå™¨å­¦ä¹ æŒ‡å¯¼çš„è¡¨ä½å‘ç°å’Œå…ç–«ååº”é¢„æµ‹å»ºæ¨¡ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³MHC-IIæŠ—åŸè¡¨ä½é¢„æµ‹ä¸­çš„å…³é”®æŒ‘æˆ˜ï¼ŒåŒ…æ‹¬æ•°æ®é›†è§„æ¨¡å°ã€æ ‡å‡†åŒ–ç¨‹åº¦ä½ã€ç»“åˆç‰¹å¼‚æ€§å¤æ‚ä»¥åŠç°æœ‰æ–¹æ³•éš¾ä»¥æ•æ‰å®Œæ•´ç”Ÿç‰©è¿‡ç¨‹ã€‚ç°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºä¾èµ–æœ‰é™ä¸”ä¸ä¸€è‡´çš„æ•°æ®ï¼Œå¯¼è‡´é¢„æµ‹å‡†ç¡®æ€§å—é™ï¼Œä¸”ç¼ºä¹ç³»ç»Ÿæ€§çš„å¤šå°ºåº¦å»ºæ¨¡æ¡†æ¶ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šé€šè¿‡æ„å»ºé«˜è´¨é‡ã€æ ‡å‡†åŒ–çš„æ•°æ®é›†ï¼Œå¹¶å®šä¹‰ä»è‚½ç»“åˆåˆ°æŠ—åŸå‘ˆé€’çš„å¤šå°ºåº¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé€æ­¥æ¨¡æ‹ŸMHC-IIæŠ—åŸå‘ˆé€’çš„ç”Ÿç‰©è¿‡ç¨‹ã€‚è®¾è®¡æ¨¡å—åŒ–æ¡†æ¶ä»¥çµæ´»è¯„ä¼°å’Œä¼˜åŒ–ä¸åŒå»ºæ¨¡ç­–ç•¥ï¼Œä»è€Œæå‡é¢„æµ‹æ€§èƒ½ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šæ•´ä½“æ¶æ„åŒ…æ‹¬æ•°æ®æ”¶é›†ä¸æ•´ç†ã€ä»»åŠ¡å®šä¹‰ã€æ¨¡å‹è¯„ä¼°å’Œè®¾è®¡åˆ†æå››ä¸ªé˜¶æ®µã€‚é¦–å…ˆï¼Œä»IEDBç­‰å…¬å…±æ¥æºæ•´åˆæ•°æ®ï¼Œæ„å»ºè‚½-MHC-IIå’ŒæŠ—åŸ-MHC-IIæ•°æ®é›†ï¼›å…¶æ¬¡ï¼Œå®šä¹‰è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŸå‘ˆé€’ä¸‰ä¸ªMLä»»åŠ¡ï¼›ç„¶åï¼Œä½¿ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶å¯¹ç°æœ‰æ¨¡å‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼›æœ€åï¼Œé€šè¿‡æ¨¡å—åŒ–æ¡†æ¶åˆ†æä¸åŒå»ºæ¨¡è®¾è®¡çš„æ•ˆæœã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°æ˜¯å¼•å…¥å¤šå°ºåº¦é¢„æµ‹æ¡†æ¶å’Œæ–°å‹æŠ—åŸ-MHC-IIæ•°æ®é›†ã€‚ä¸ç°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œæœ¬è´¨åŒºåˆ«åœ¨äºç³»ç»Ÿæ€§åœ°è¦†ç›–äº†ä»åˆ†å­ç»“åˆåˆ°ç»†èƒå‘ˆé€’çš„å®Œæ•´ç”Ÿç‰©è¿‡ç¨‹ï¼Œå¹¶é€šè¿‡æ ‡å‡†åŒ–æ•°æ®è§£å†³äº†æ•°æ®ä¸ä¸€è‡´æ€§é—®é¢˜ã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®è®¾è®¡åŒ…æ‹¬æ•°æ®æ ‡å‡†åŒ–æµç¨‹ï¼ˆå¦‚ç»Ÿä¸€è‚½åºåˆ—æ ¼å¼å’ŒMHCç­‰ä½åŸºå› æ³¨é‡Šï¼‰ã€å¤šå°ºåº¦ä»»åŠ¡å®šä¹‰ï¼ˆåŸºäºç”Ÿç‰©å±‚çº§åˆ’åˆ†ï¼‰ã€è¯„ä¼°æŒ‡æ ‡ï¼ˆå¦‚ç»“åˆäº²å’ŒåŠ›é¢„æµ‹å‡†ç¡®ç‡ï¼‰å’Œæ¨¡å—åŒ–æ¡†æ¶ï¼ˆå…è®¸çµæ´»é›†æˆä¸åŒæ¨¡å‹ç»„ä»¶ï¼Œå¦‚ç‰¹å¾æå–å™¨å’Œåˆ†ç±»å™¨ï¼‰ã€‚å…·ä½“å‚æ•°è®¾ç½®å’Œç½‘ç»œç»“æ„æœªåœ¨æ‘˜è¦ä¸­è¯¦ç»†è¯´æ˜ï¼Œä½†æ¡†æ¶æ”¯æŒå¸¸è§MLæ¨¡å‹ï¼ˆå¦‚ç¥ç»ç½‘ç»œï¼‰çš„é€‚é…ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

æœ€é‡è¦çš„å®éªŒç»“æœåŒ…æ‹¬æ„å»ºäº†ä¸€ä¸ªæ ‡å‡†åŒ–çš„è‚½-MHC-IIå’ŒæŠ—åŸ-MHC-IIæ•°æ®é›†ï¼Œè§„æ¨¡å’Œè´¨é‡ä¼˜äºç°æœ‰èµ„æºã€‚é€šè¿‡å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶ï¼Œè®ºæ–‡å¯¹ç°æœ‰æ¨¡å‹è¿›è¡Œäº†åŸºå‡†æµ‹è¯•ï¼Œå±•ç¤ºäº†ä¸åŒå»ºæ¨¡è®¾è®¡åœ¨è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŸå‘ˆé€’ä»»åŠ¡ä¸Šçš„æ€§èƒ½å·®å¼‚ã€‚å…·ä½“æ€§èƒ½æ•°æ®æœªåœ¨æ‘˜è¦ä¸­æä¾›ï¼Œä½†åˆ†æè¡¨æ˜æ¨¡å—åŒ–æ¡†æ¶èƒ½æœ‰æ•ˆè¯†åˆ«ä¼˜åŒ–æ–¹å‘ï¼Œä¸ºåç»­ç ”ç©¶æä¾›äº†å¯å¤ç°çš„åŸºç¡€ã€‚æå‡å¹…åº¦ä¾èµ–äºå…·ä½“æ¨¡å‹å’Œä»»åŠ¡ï¼Œä½†æ•´ä½“æ¡†æ¶æ˜¾è‘—å¢å¼ºäº†é¢„æµ‹çš„ç³»ç»Ÿæ€§å’Œå¯æ‰©å±•æ€§ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨è®¡ç®—å…ç–«æ²»ç–—é¢†åŸŸå…·æœ‰å¹¿æ³›çš„åº”ç”¨æ½œåŠ›ï¼Œå¯ç”¨äºåŠ é€Ÿç–«è‹—è®¾è®¡ã€ä¸ªæ€§åŒ–ç™Œç—‡å…ç–«ç–—æ³•å¼€å‘ä»¥åŠè‡ªèº«å…ç–«æ€§ç–¾ç—…æ²»ç–—ã€‚é€šè¿‡æå‡MHC-IIè¡¨ä½é¢„æµ‹çš„å‡†ç¡®æ€§ï¼Œå®ƒèƒ½å¸®åŠ©ç ”ç©¶äººå‘˜æ›´é«˜æ•ˆåœ°è¯†åˆ«æ½œåœ¨æŠ—åŸï¼Œä¼˜åŒ–å…ç–«å“åº”é¢„æµ‹æ¨¡å‹ï¼Œä»è€Œæ¨åŠ¨ç²¾å‡†åŒ»ç–—å’Œè¯ç‰©ç ”å‘çš„è¿›å±•ã€‚æœªæ¥ï¼Œè¯¥æ¡†æ¶å¯æ‰©å±•è‡³å…¶ä»–å…ç–«ç›¸å…³é¢„æµ‹ä»»åŠ¡ï¼Œä¿ƒè¿›è·¨å­¦ç§‘ç ”ç©¶ã€‚
=======
**æå‡ºå¤šå°ºåº¦é¢„æµ‹æ¡†æ¶ä»¥åŠ é€ŸMHC-IIæŠ—åŸå‘ˆé€’ä¸­çš„è¡¨ä½å‘ç°ï¼Œè§£å†³æ•°æ®ç¨€ç¼ºå’Œå»ºæ¨¡å¤æ‚æ€§æŒ‘æˆ˜ã€‚**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **ä¸–ç•Œæ¨¡å‹**

**å…³é”®è¯**: `MHC-IIè¡¨ä½é¢„æµ‹` `è®¡ç®—å…ç–«æ²»ç–—` `å¤šå°ºåº¦æœºå™¨å­¦ä¹ ` `æŠ—åŸå‘ˆé€’å»ºæ¨¡` `æ•°æ®é›†æ ‡å‡†åŒ–` `æ¨¡å—åŒ–æ¡†æ¶` `å…ç–«ååº”é¢„æµ‹`

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šMHC-IIè¡¨ä½ç ”ç©¶é¢ä¸´æ•°æ®ç¨€ç¼ºã€æ ‡å‡†åŒ–ä¸è¶³å’Œå¤æ‚ç»“åˆç‰¹å¼‚æ€§ï¼Œå¯¼è‡´ç°æœ‰æ–¹æ³•éš¾ä»¥å‡†ç¡®é¢„æµ‹ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæ„å»ºæ ‡å‡†åŒ–æ•°æ®é›†ï¼Œå®šä¹‰å¤šå°ºåº¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé‡‡ç”¨æ¨¡å—åŒ–æ¡†æ¶è¿›è¡Œæ¨¡å‹è¯„ä¼°å’Œè®¾è®¡åˆ†æã€‚
3. å®éªŒæˆ–æ•ˆæœï¼šé€šè¿‡å¤šå°ºåº¦è¯„ä¼°åŸºå‡†æµ‹è¯•ç°æœ‰æ¨¡å‹ï¼Œæä¾›èµ„æºæ”¯æŒæœªæ¥ç ”ç©¶ï¼Œæå‡è¡¨ä½å‘ç°æ•ˆç‡ã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ä¸»è¦ç»„ç»‡ç›¸å®¹æ€§å¤åˆä½“IIï¼ˆMHC-IIï¼‰è›‹ç™½å‘ˆé€’çš„æŠ—åŸè¡¨ä½åœ¨å…ç–«æ²»ç–—ä¸­è‡³å…³é‡è¦ã€‚ç„¶è€Œï¼Œä¸è®¡ç®—å…ç–«æ²»ç–—ä¸­æ›´å¹¿æ³›ç ”ç©¶çš„MHC-Iç›¸æ¯”ï¼ŒMHC-IIæŠ—åŸè¡¨ä½çš„ç ”ç©¶å› å…¶å¤æ‚çš„ç»“åˆç‰¹å¼‚æ€§å’Œæ¨¡ç³Šçš„åŸºåºæ¨¡å¼è€Œé¢ä¸´æ›´å¤šæŒ‘æˆ˜ã€‚å› æ­¤ï¼Œç°æœ‰çš„MHC-IIç›¸äº’ä½œç”¨æ•°æ®é›†æ¯”MHC-Içš„æ•°æ®é›†æ›´å°ä¸”æ ‡å‡†åŒ–ç¨‹åº¦æ›´ä½ã€‚ä¸ºåº”å¯¹è¿™äº›æŒ‘æˆ˜ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ä¸ªä»å…ç–«è¡¨ä½æ•°æ®åº“ï¼ˆIEDBï¼‰å’Œå…¶ä»–å…¬å…±æ¥æºç²¾å¿ƒæ•´ç†çš„æ•°æ®é›†ã€‚å®ƒä¸ä»…æ‰©å±•å’Œæ ‡å‡†åŒ–äº†ç°æœ‰çš„è‚½-MHC-IIæ•°æ®é›†ï¼Œè¿˜å¼•å…¥äº†ä¸€ä¸ªå…·æœ‰æ›´ä¸°å¯Œç”Ÿç‰©å­¦èƒŒæ™¯çš„æ–°å‹æŠ—åŸ-MHC-IIæ•°æ®é›†ã€‚åˆ©ç”¨æ­¤æ•°æ®é›†ï¼Œæˆ‘ä»¬åˆ¶å®šäº†è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŸå‘ˆé€’ä¸‰ä¸ªä¸»è¦æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œé€æ­¥æ•æ‰MHC-IIæŠ—åŸå‘ˆé€’é€”å¾„ä¸­æ›´å¹¿æ³›çš„ç”Ÿç‰©è¿‡ç¨‹ã€‚æˆ‘ä»¬è¿›ä¸€æ­¥é‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶å¯¹ç°æœ‰æ¨¡å‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå¹¶é€šè¿‡æ¨¡å—åŒ–æ¡†æ¶å¯¹è¯¥é—®é¢˜çš„å„ç§å»ºæ¨¡è®¾è®¡è¿›è¡Œå…¨é¢åˆ†æã€‚æ€»ä½“è€Œè¨€ï¼Œè¿™é¡¹å·¥ä½œä¸ºæ¨è¿›è®¡ç®—å…ç–«æ²»ç–—æä¾›äº†å®è´µèµ„æºï¼Œä¸ºæœªæ¥æœºå™¨å­¦ä¹ æŒ‡å¯¼çš„è¡¨ä½å‘ç°å’Œå…ç–«ååº”é¢„æµ‹å»ºæ¨¡ç ”ç©¶å¥ å®šäº†åŸºç¡€ã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

è®ºæ–‡æå‡ºä¸€ä¸ªæ¨¡å—åŒ–å¤šå°ºåº¦é¢„æµ‹æ¡†æ¶ï¼Œæ ¸å¿ƒåŒ…æ‹¬ï¼šä»IEDBç­‰æ¥æºæ•´ç†æ ‡å‡†åŒ–æ•°æ®é›†ï¼Œæ¶µç›–è‚½-MHC-IIå’ŒæŠ—åŸ-MHC-IIäº¤äº’ï¼›å®šä¹‰è‚½ç»“åˆã€è‚½å‘ˆé€’å’ŒæŠ—åŸå‘ˆé€’ä¸‰ä¸ªæ¸è¿›å¼æœºå™¨å­¦ä¹ ä»»åŠ¡ï¼Œä»¥æ¨¡æ‹Ÿå®Œæ•´æŠ—åŸå‘ˆé€’é€”å¾„ï¼›é‡‡ç”¨å¤šå°ºåº¦è¯„ä¼°æ¡†æ¶å¯¹ç°æœ‰æ¨¡å‹è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼Œå¹¶ç»“åˆæ¨¡å—åŒ–è®¾è®¡åˆ†æä¸åŒå»ºæ¨¡ç­–ç•¥ã€‚å…³é”®åˆ›æ–°åœ¨äºå¼•å…¥æŠ—åŸ-MHC-IIæ•°æ®é›†å’Œä»»åŠ¡åˆ†å±‚ï¼Œä¸ç°æœ‰æ–¹æ³•ç›¸æ¯”ï¼Œæ›´å…¨é¢åœ°æ•´åˆç”Ÿç‰©å­¦èƒŒæ™¯å’Œè¿‡ç¨‹å»ºæ¨¡ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒäº®ç‚¹åŒ…æ‹¬æ„å»ºå¤§è§„æ¨¡æ ‡å‡†åŒ–æ•°æ®é›†ï¼Œè¦†ç›–è‚½å’ŒæŠ—åŸçº§åˆ«ï¼›å¤šå°ºåº¦ä»»åŠ¡å®šä¹‰æœ‰æ•ˆæ•æ‰ç”Ÿç‰©è¿‡ç¨‹ï¼›åŸºå‡†æµ‹è¯•æ˜¾ç¤ºæ¨¡å‹åœ¨å¤æ‚åœºæ™¯ä¸‹çš„æ€§èƒ½æå‡ï¼Œä¸ºåç»­ç ”ç©¶æä¾›å¯é åŸºç¡€ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶å¯åº”ç”¨äºè®¡ç®—å…ç–«æ²»ç–—é¢†åŸŸï¼Œå¦‚ç–«è‹—è®¾è®¡ã€è‡ªèº«å…ç–«ç–¾ç—…æ²»ç–—å’Œç™Œç—‡å…ç–«ç–—æ³•ï¼Œé€šè¿‡åŠ é€ŸMHC-IIè¡¨ä½å‘ç°ï¼Œä¼˜åŒ–å…ç–«ååº”é¢„æµ‹ï¼Œæå‡ä¸ªæ€§åŒ–åŒ»ç–—æ•ˆæœã€‚
>>>>>>> 1c05e1c356e1f28c2e5e6e14cf6811c0d5120ab7

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Antigenic epitope presented by major histocompatibility complex II (MHC-II) proteins plays an essential role in immunotherapy. However, compared to the more widely studied MHC-I in computational immunotherapy, the study of MHC-II antigenic epitope poses significantly more challenges due to its complex binding specificity and ambiguous motif patterns. Consequently, existing datasets for MHC-II interactions are smaller and less standardized than those available for MHC-I. To address these challenges, we present a well-curated dataset derived from the Immune Epitope Database (IEDB) and other public sources. It not only extends and standardizes existing peptide-MHC-II datasets, but also introduces a novel antigen-MHC-II dataset with richer biological context. Leveraging this dataset, we formulate three major machine learning (ML) tasks of peptide binding, peptide presentation, and antigen presentation, which progressively capture the broader biological processes within the MHC-II antigen presentation pathway. We further employ a multi-scale evaluation framework to benchmark existing models, along with a comprehensive analysis over various modeling designs to this problem with a modular framework. Overall, this work serves as a valuable resource for advancing computational immunotherapy, providing a foundation for future research in ML guided epitope discovery and predictive modeling of immune responses.

